WO2015141926A1 - Composition for inhibiting or alleviating skin aging caused by stress stimulation, containing trapa japonica as active ingredient - Google Patents
Composition for inhibiting or alleviating skin aging caused by stress stimulation, containing trapa japonica as active ingredient Download PDFInfo
- Publication number
- WO2015141926A1 WO2015141926A1 PCT/KR2014/011418 KR2014011418W WO2015141926A1 WO 2015141926 A1 WO2015141926 A1 WO 2015141926A1 KR 2014011418 W KR2014011418 W KR 2014011418W WO 2015141926 A1 WO2015141926 A1 WO 2015141926A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- skin
- extract
- fraction
- lotion
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 230000009759 skin aging Effects 0.000 title claims abstract description 31
- 230000004938 stress stimulation Effects 0.000 title claims abstract description 13
- 239000004480 active ingredient Substances 0.000 title claims abstract description 8
- 230000002401 inhibitory effect Effects 0.000 title abstract description 35
- 241001428357 Trapa japonica Species 0.000 title abstract 4
- 239000000284 extract Substances 0.000 claims abstract description 58
- 239000002537 cosmetic Substances 0.000 claims abstract description 10
- 206010051246 Photodermatosis Diseases 0.000 claims description 26
- 230000008845 photoaging Effects 0.000 claims description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 24
- 239000006210 lotion Substances 0.000 claims description 20
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 239000006071 cream Substances 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 235000016709 nutrition Nutrition 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- -1 foundation Substances 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical class 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 235000015927 pasta Nutrition 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 150000005846 sugar alcohols Polymers 0.000 claims description 2
- 241000219422 Urtica Species 0.000 claims 2
- 235000009108 Urtica dioica Nutrition 0.000 claims 2
- 150000001298 alcohols Chemical class 0.000 claims 1
- 229940072117 fennel extract Drugs 0.000 claims 1
- 239000008269 hand cream Substances 0.000 claims 1
- 210000003491 skin Anatomy 0.000 abstract description 41
- 230000014509 gene expression Effects 0.000 abstract description 31
- 238000002360 preparation method Methods 0.000 abstract description 14
- 210000004207 dermis Anatomy 0.000 abstract description 9
- 102000008645 11-beta-Hydroxysteroid Dehydrogenase Type 1 Human genes 0.000 abstract description 3
- 108010088011 11-beta-Hydroxysteroid Dehydrogenase Type 1 Proteins 0.000 abstract description 3
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract description 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract description 3
- 230000007423 decrease Effects 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 26
- 230000032683 aging Effects 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 210000002950 fibroblast Anatomy 0.000 description 10
- 230000002757 inflammatory effect Effects 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000002500 effect on skin Effects 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 108060003393 Granulin Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 235000019439 ethyl acetate Nutrition 0.000 description 5
- 239000003862 glucocorticoid Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000002438 stress hormone Substances 0.000 description 4
- 229940037128 systemic glucocorticoids Drugs 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 2
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 206010072170 Skin wound Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- KVUXYQHEESDGIJ-UHFFFAOYSA-N 10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthrene-3,16-diol Chemical compound C1CC2CC(O)CCC2(C)C2C1C1CC(O)CC1(C)CC2 KVUXYQHEESDGIJ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 244000186654 Fockea angustifolia Species 0.000 description 1
- 235000015210 Fockea angustifolia Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102000007451 Steroid Receptors Human genes 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 108091008723 corticosteroid receptors Proteins 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000006355 external stress Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 125000001288 lysyl group Chemical group 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0216—Solid or semisolid forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
Definitions
- composition for inhibiting or improving skin aging due to stress stimulation containing twill extract as an active ingredient
- the present invention is made by the task number HN12C0061 in support of the Ministry of Health and Welfare, the research management professional organization of the task is a global cosmetic research and development project,
- the present invention relates to a composition for inhibiting or improving skin aging due to stress stimulation containing a twill extract as an active ingredient, and more specifically for inhibiting or improving skin aging due to stress stimulation containing a twill extract or a twill fraction as an active ingredient. It relates to a cosmetic composition or a topical skin composition.
- Aging refers to the gradual decline in physiological function of normal function as a result of complex human mechanisms.
- the skin contains keratinocytes, melanocytes, islets of Langerhans, fibroblasts and adipocytes. These cells undergo aging and change in physiological function, shape, and structure.
- Skin aging is divided into two types: intr ic aging and photoaging. Endogenous aging is irrelevant to the external environment with the passage of time. It refers to the aging phenomenon that occurs naturally depending on the genetic factors. On the other hand, photoaging is a phenomenon caused by external environmental factors and can be avoided because it can be artificially controlled. The representative factor of photoaging is ultraviolet light, which leads to the activation of proteolytic enzymes, chain breakage of substrate proteins and damage of biological components of abnormal cross-links, and repetition of this mechanism leads to apparent skin aging. .
- Wrinkles, decreased skin elasticity, sagging and dryness in aged skin are mostly due to changes in matrix proteins present in the dermis.
- the dermis is located directly below the epidermis and determines the strength and shape of the skin. Therefore, when aging progresses, morphological changes occur in this area, which leads to a change in elasticity.
- Ps Moatr ix metal loproteinases
- ⁇ P activity is increased in the skin even with a single UV irradiation, and it significantly degrades collagen and other substrate proteins in the skin to promote skin aging. It acts as a major factor.
- Intracellular reactions by stress are reactions of glucocorticoids acting as stress hormones and are regulated by secretion of active cortisol and ⁇ ⁇ -HSDl (11 ⁇ -hydroxysteroid dehydrogenasel) activity.
- ⁇ ⁇ -HSDl converts inactive glucocorticoids into active glucocorticoids, thereby playing an important role in regulating the concentration of cellular agents and activating corticosteroid receptors in target tissues.
- ⁇ ⁇ -HSDl converts inactive glucocorticoids into active glucocorticoids, thereby playing an important role in regulating the concentration of cellular agents and activating corticosteroid receptors in target tissues.
- the present inventors have made diligent research efforts to overcome the problems of the prior art, to discover that the role of ⁇ -HSDl activated by ultraviolet light is related to photoaging and to find a substance that improves the efficacy of anti-aging Based on the plant extracts reported to have been compared and selected, among them, the extracts of the filth extract or its fractions, ⁇ ⁇ -HSDl and ⁇ Ps, the expression of inflammatory factors and the thickness of the dermis . It has been confirmed that the inhibition of skin aging, the improvement and treatment of aging skin can be suppressed, and the present invention has been completed.
- the main object of the present invention is to inhibit the skin aging by inhibiting the expression of ⁇ -HSDl and ⁇ Ps, the expression of inflammatory factors and the thickness of the dermis, which has the effect of improving the aging skin. It is to provide a composition for inhibiting or improving skin aging due to stress stimulation containing a twill extract or a twill fraction as an active ingredient.
- Another object of the present invention is to provide a method for use in the preparation of a composition for inhibiting or improving skin aging due to stress stimulation of the stalk extract or stalk fraction or a method for inhibiting or improving skin aging using such a composition.
- the present invention provides a composition for inhibiting or improving skin aging due to stress stimulation, which contains an extract of the stalk extract or the stalk fraction as an active ingredient.
- the composition is characterized in that it is used as a cosmetic or skin external preparation.
- Thunsil is a yearly grass that grows in water and has elongated stems. Each node floats in the shape of a feather-shaped water root. This insufficiency is effective in nourishing and tonic, so the body is a good nutritional to the weak, it is known to detoxify and act as a detoxification.
- Korean Patent No. 10-0927970 discloses that the extract of twill is effective in inhibiting sebum secretion and acne.
- the present inventors have found that the twill extract has an effect of suppressing skin photoaging due to stress stimulation, in particular, stress stimulation by ultraviolet rays, and thus, the present invention has been completed.
- the term 'stress stimulus' of the present invention means that harmful stimuli from the external environment increase the stress hormone (glucocorticoid) in the skin and cause skin aging or skin atrophy. In the present invention, it means specifically by stress stimulation by ultraviolet rays.
- the skin aging may be photoaging by ultraviolet rays, moreover.
- it is characterized by photoaging by UVB Jl travi olet B).
- the term 'photo-aging (Phhtoagipg)' of the present invention is a phenomenon caused by external environmental factors, and the most representative factor is ultraviolet rays. This ultraviolet light causes damage to biological components such as protease activation, substrate protein chain breakdown and abnormal crosslinking, and the repetition of this mechanism leads to apparent skin aging. That is, in the present invention, unlike endogenous aging caused by genetic factors regardless of the external environment, a composition for inhibiting or improving skin aging caused by photoaging caused by ultraviolet rays, in particular a cosmetic composition, or It relates to an external preparation composition for skin.
- the twill extract can be extracted with any solvent conventionally used .
- water, lower alcohol having 1 to 4 carbon atoms, polyhydric alcohol having 3 to 6 carbon atoms, glycerin, propylene glycol or butylene glycol is characterized in that the extraction with one or more solvents selected from the group consisting of.
- the lysyl fraction can be fractionated by any solvent used in the conventional systematic fractionation method, preferably a low polar organic solvent, more preferably nucleic acid, methylene chloride, ethyl acetate or n -Fractionate with at least one solvent selected from the group consisting of butanol.
- a low polar organic solvent more preferably nucleic acid, methylene chloride, ethyl acetate or n -Fractionate with at least one solvent selected from the group consisting of butanol.
- the twill extract or the twill fraction may be used as it is, characterized in that it can be used in the form of a concentrated lyophilized or lyophilized after filtration.
- the skin aging is 11 beta-HSD 1 (11 ⁇ _ It is characterized by inhibiting or improving skin aging by inhibiting the expression of hydroxysteroid dehydrogenasel).
- 11beta-HSD1 (11 ⁇ -hydroxysteroid dehydrogenasel, ⁇ -HSDl) regulates the reaction of glucocorticoids to act as stress hormones.
- ⁇ -HSDl increases Î ⁇ -HSDl activity in the skin with age (Tiganescu A et al, 2013; 123 (7): 3051-3060).
- the researchers found that the activity of ⁇ -HSDl at the site where photoaging occurred was about 4 times higher than the site where endogenous aging occurred. Reported (Tiganescu A et al, 2011; 131, 30-36).
- the skin aging is characterized by inhibiting or improving skin aging by inhibiting the expression of ⁇ Ps and inflammatory factors.
- ⁇ Ps (Matrix metal loproteinases) is increased ⁇ P activity in the skin in a single UV irradiation Representative enzymes that break down matrix proteins and i to to significantly decompose collagen and other matrix proteins in the skin, it promotes skin aging increases important factor Acts as.
- the skin aging is characterized in that to suppress or improve the skin aging by inhibiting the reduction of the dermal layer thickness.
- the twill extract or the twill fraction is characterized in that it comprises 0.01 to 90% by weight relative to the total weight of the composition. If it is outside the above range, the formulation is not easy and is not preferable.
- the composition may be prepared in any formulation commonly prepared in the art, for example, emulsion, cream, lotion, pack, foundation, lotion, essence, hair cosmetics, etc. .
- Cosmetic compositions of the present invention may include other auxiliaries in addition to the carrier, for example, may include preservatives, antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors.
- the composition may be used in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, and other external preparations and sterile injectable solutions, respectively, according to a conventional method. May have a cream, gel, patch, spray, ointment, warning, lotion, liniment pasta or cataplasma formulation.
- Carriers, excipients, and diluents that may be included in the composition include lactose, dextrose, sucrose, oligosaccharides, sorbbi, manny, xili, and erythritol. Malty, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, Talc, magnesium stearate and mineral oil.
- diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants are usually used.
- Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like. Such solid preparations may contain at least one excipient such as starch, calcium carbonate, water, or the like. Prepared with a mixture of sucrose or lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium styrate talc are also used. Oral liquid preparations include suspending agents, liquid solutions, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. .
- Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
- non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used.
- base of the suppository wi tepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
- the preferred dosage of the composition also depends on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art. However, for the desired effect, the composition of the present invention is preferably administered at 0.0001 to 100mg / kg, preferably 0.001 to 10mg / kg per day. Topical administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
- the filth extract or fraction extract of the present invention inhibits the expression of ⁇ ⁇ -HSDl, MMPs and inflammatory factors overexpressed by UV light.
- the filth extract or fraction extract of the present invention inhibits the expression of ⁇ ⁇ -HSDl, MMPs and inflammatory factors overexpressed by UV light.
- Figure 1 is a picture of the results of Experimental Example 1 measuring the effect on the expression of ⁇ ⁇ -HSDl protein 'in the treatment of the extract and fractions in human fibroblasts.
- Figure 2 is a graph of the results of Experimental Example 2 measuring the effect on the P-1 protein expression in the treatment of the extract and fractions in human fibroblasts.
- Figure 3 is a graph of the results of Experimental Example 3 measuring the effect on ⁇ P-3 messenger RNA expression in the treatment of the extract and fractions in human fibroblasts.
- FIG. 4 is a graph showing the results of Experimental Example 3, which measured the effect of fflP-9 messenger R A expression upon treatment of filth extract and fraction on human fibroblasts.
- Figure 5 is a graph of the results of Experimental Example 4 measuring the effect on the C0X-2 messenger RNA expression when treatment with the extract and fractions in human keratinocytes.
- Figure 6 is a graph of the results of Experimental Example 4 measuring the effect on the expression of iNOS messenger R A in the treatment of extracts and fractions in human keratinocytes.
- Figure 7 is a graph of the results of Experimental Example 5 measuring the effect on the P-1 protein expression in the treatment of the extract and fractions in the three-dimensional artificial skin.
- Figure 8 is a graph of the results of Experimental Example 6 measuring the effect on the change in the thickness of the dermis layer during the treatment of the sample containing the twill extract in the photo-aging skin animal model.
- Tungsil used in the present invention was purchased from the herbal medicine of Gyeongdong market, Seoul, Korea.
- Electrophoresis using SDS-PAGE Sod i umdodecy 1 su 1 f at e-po 1 yacry 1 am i de gel electrophoresis
- transfer protein bands to PVDF Polyvinyl idene fluoride, Bio-rad, USA
- Enhanced chemi luminescence, ThermoScient if ic, USA was confirmed the amount of protein expression.
- RT-PCR was performed using a PCR machine (Step One Plus, Applied Biosystems, USA) and assayed by the addition of cyberrin (SYBRGreen supermix, Applied Biosystems, USA) with P-3 and P-9 primers and cDNA.
- the primer and reaction conditions were shown in Table 1 below, and the expression levels of ⁇ P-3 and ⁇ P-9 were expressed by correcting the ⁇ -actin gene.
- Human keratinocytes were cultured in the same manner as described in Experimental Example 3 above, the cells were inoculated into 6 we ll plates and irradiated with UVB 15mJ after 24 hours, and then each extract was added. After further incubation for 24 hours, real-t ime RT-PCR was carried out in the same manner as in Experiment 2 to measure messenger RNA expression levels of inflammatory factors C0X-2 ( C yc looxygenase_2) and iNOS (inducibl e NO synthase).
- C0X-2 C yc looxygenase_2
- iNOS inducibl e NO synthase
- Example 5 MMP-1 Inhibitory Activity of Twill Extract in Three-Dimensional Skin Tissues
- P-1 expression of the twill extract of Example 1 was confirmed using three-dimensional artificial skin tissue.
- Epi dermal ti ssue (Skin Ethi cs, Nikoderm Research Inc., France) was stabilized in growth medi a for 24 hours, and then irradiated with UVB 40mJ. Enzyme-linked immunosorbent assay (enzyme- l inked) to quantify the amount of protein secretion of ⁇ P-1 after incubation for 72 hours An immunosorbent assay (ELISA) was performed.
- the effect of the sample containing the twill extract of Example 1 on the photoaging skin animal model was evaluated. Dermal mice were irradiated with ultraviolet rays three times a week for a total of eight weeks, and the samples containing the twill methanol extract were mixed with the base and applied twice a day for a total of eight weeks to measure dermal thickness.
- the base was mixed with PG (propylene glycol): EtOH (ethane) at 7: 3 and treated with sham light to serve as a control.
- the toner agent containing the extract obtained in Example 1 was prepared in a conventional manner according to the composition components and composition ratios shown in Table 2 below.
- the cream containing the extract obtained in Example 1 was prepared in a conventional manner according to the composition components and composition ratios shown below.
- Example 1 ⁇ 1 1.0 Glyceryl Stearate / Sebum -1 00 Stearate 2.0 Fully Solate 60 0.5
Abstract
The present invention relates to a cosmetic composition or an external use skin preparation composition for inhibiting or alleviating skin aging caused by stress stimulation, containing a Trapa japonica extract or a Trapa japonica fraction as an active ingredient. According to the present invention, the Trapa japonica extract or a fraction thereof can inhibit skin aging and alleviate and treat the aged skin by inhibiting 11β-HSD1 and MMPs, the expression of inflammation factors and a decrease in dermis thickness.
Description
【명세서】 【Specification】
【발명의 명칭】 [Name of invention]
능실 추출물을 유효성분으로 함유하는 스트레스 자극에 의한 피부노화 억제 또는 개선용 조성물 Composition for inhibiting or improving skin aging due to stress stimulation containing twill extract as an active ingredient
【기술분야】 Technical Field
본 발명은 대한민국 보건복지부 지원하에 과제번호 HN12C0061에 의해 이루어진 것으로서， 상기 과제의 연구관리전문기관은 글로벌코스메틱연구개발사업단, 연구사업명은 The present invention is made by the task number HN12C0061 in support of the Ministry of Health and Welfare, the research management professional organization of the task is a global cosmetic research and development project,
"글로벌화장품신소재 ·신기술연구개발지원" 연구과제명은 "피부세포 핵수용체 조절 천연물 허브 구축을 통한 한류 화장품 개발" ， 주관기관은 코스맥스 (주) , 연구기간은 2013. 11.01 - 2014. 10.31이다. "Global Cosmetics New Materials and New Technology R & D Support" research title is "Development of Korean Wave Cosmetics by Establishment of Skin Cell Nuclear Receptor-regulated Natural Herbs", Hosted by Cosmax Co., Ltd. and research period is 2013.11.01-2014.10.31.
본 발명은 능실 추출물을 유효성분으로 함유하는 스트레스 자극에 의한 피부노화 억제 또는 개선용 조성물에 관한 것으로， 더욱 구체적으로 능실 추출물 또는 능실 분획물을 유효성분으로 함유하는 스트레스 자극에 의한 피부노화 억제 또는 개선용 화장료 조성물 또는 피부외용제 조성물에 관한 것이다. The present invention relates to a composition for inhibiting or improving skin aging due to stress stimulation containing a twill extract as an active ingredient, and more specifically for inhibiting or improving skin aging due to stress stimulation containing a twill extract or a twill fraction as an active ingredient. It relates to a cosmetic composition or a topical skin composition.
【배경기술】 Background Art
피부는 나이가 들면서 자연스럽게 노화가 진행되고 이는 다양한 외부적 자극에 의해서 촉진되거나 감소된다. 노화는 복잡한 인체 메커니즘에 의한 결과로서 본래 가지고 있는 정상적인 기능이 생리학적으로 점차 쇠퇴하는 것을 일컫는다. As the skin ages, it naturally ages and is promoted or reduced by various external stimuli. Aging refers to the gradual decline in physiological function of normal function as a result of complex human mechanisms.
피부에는 각질형성세포, 멜라닌세포， 랑게르한스섬， 섬유아세포， 지방세포 등이 존재하고 있다. 이러한 세포들은 노화현상을 거치면서 생리적 기능 및 형태， 구조가 변화하게 된다. The skin contains keratinocytes, melanocytes, islets of Langerhans, fibroblasts and adipocytes. These cells undergo aging and change in physiological function, shape, and structure.
피부노화는 내인성 노화 ( intr ins i c aging)와 광노화 (Photoaging) 두 가지 형태로 구분되는데， 내인성 노화는 세월의 흐름에 따라 외부환경과는 무관하게
유전적 요소에 영향에 따라 자연스럽게 나타나는 노화현상을 일컫는다. 광노화는 이와 반대로 외부 환경적인 요인에 의해 유발되는 현상으로 인위적으로 조절이 가능하여 상당부분 피할 수 있다. 광노화의 대표적인 인자는 자외선으로， 이는 단백질 분해효소의 활성화와 기질단백질의 사슬절단 및 비정상적인 교차결합 둥의 생체 구성 성분들의 손상을 가져오고， 이러한 메커니즘의 반복은 외관상으로도 확연한 피부노화를 초래하게 된다. Skin aging is divided into two types: intr ic aging and photoaging. Endogenous aging is irrelevant to the external environment with the passage of time. It refers to the aging phenomenon that occurs naturally depending on the genetic factors. On the other hand, photoaging is a phenomenon caused by external environmental factors and can be avoided because it can be artificially controlled. The representative factor of photoaging is ultraviolet light, which leads to the activation of proteolytic enzymes, chain breakage of substrate proteins and damage of biological components of abnormal cross-links, and repetition of this mechanism leads to apparent skin aging. .
광노화의 임상적 특징은 자연 노화에 비하여 확연히 구분된다. 굵고 깊은 주름이 발생하며 피부가 매우 거칠고 건조해지고 쳐짐 현상도 발생한다. 광노화가 진행된 피부에서는 주름뿐만 아니라 여러 가지 광노화성 피부질환이 발생하여 피부에 불규칙한 색소침착 (주근깨， 잡티, 칙칙한 피부)을 형성하게 되고 심하게는 혹자， 검버섯, 피부암 등이 발생될 수도 있다. The clinical characteristics of photoaging are clearly distinguished from natural aging. Thick, deep wrinkles occur, and the skin becomes very rough, dry, and sagging. In photo-aged skin, not only wrinkles but also various photo-aging skin diseases may occur, resulting in irregular pigmentation (freckles, blemishes, dull skin), and severely cracked skin, black spots, and skin cancer.
노화된 피부에서 나타나는 주름살과 피부의 탄력 감소, 피부 쳐짐 및 건조 현상 등은 대부분 진피에 존재하는 기질단백질의 변화 때문이다. 진피는 표피 바로 아래에 존재하여 피부의 강도와 형태를 결정하고 있기 때문에 노화가 진행될 때 이 부분에 형태적인 변화가 일어나게 되면 탄력에 변화가 올 수밖에 없다. 이러한 기질단백질을 분해하는 효소로 醒 Ps(Matr ix metal loproteinases)가 대표적이며 한번의 자외선 조사에도 피부 내의 醒 P 활성이 증가되고， 피부 내의 콜라겐 및 기타 기질단백질을 현저하게 분해시켜 피부 노화를 촉진하는데 주요한 요인으로 작용한다. Wrinkles, decreased skin elasticity, sagging and dryness in aged skin are mostly due to changes in matrix proteins present in the dermis. The dermis is located directly below the epidermis and determines the strength and shape of the skin. Therefore, when aging progresses, morphological changes occur in this area, which leads to a change in elasticity. As the enzyme that decomposes these matrix proteins, Ps (Matr ix metal loproteinases) is representative, and 醒 P activity is increased in the skin even with a single UV irradiation, and it significantly degrades collagen and other substrate proteins in the skin to promote skin aging. It acts as a major factor.
스트레스에 따른 세포 내 반웅은 스트레스 호르몬으로 작용하는 글루코코르티코이드의 반웅으로， 활성 코르티솔의 분비와 ΙΙ β -HSDl ( 11 β - hydroxysteroid dehydrogenasel) 활성에 의해 조절된다. 이때， ΙΙ β -HSDl은 불활성 글루코코르티코이드를 활성 글루코코르티코이드로 전환시키며 이에 의해 세포작용 물질의 농도조절 및 표적 조직에서 코르티코스테로이드 수용체의 활성화에 중요한 역할을 한다. 최근 피부에서의 ΙΙ β -HSDl에 대한 흥미로운 논문이 발표되었는데 여성의 피부조직에 대한 실험 결과， 나이가 듦에 따라 피부에서의 ΙΙ β -HSDl의 활성이 증가하며， 또한, 섬유아세포에서의 그 발현량이 증가한다고 보고하였다 (Tiganescu A et al， 2013； 123(7) : 3051-3060) . 덧붙여，
폐경 전후의 피부 조직을 비교할 때 진피에서 본 효소의 상당한 증가를 확인하였다. 또한， 본 연구팀의 발표에 따르면, 사람의 팔에서 광노화가 진행된 부위와 내인성 노화가 주로 진행되는 부위에 대해 ΙΙ β -HSDl 활성 정도를 비교한 결과， 광노화가 일어나는 부위에서의 ΙΙβ -HSDl의 활성도가 내인성 노화가 일어나는 부위에 비해 약 4배 이상 높다고 보고하였다 (Tiganescu A et al , 2011；131 , 30-36) . 이러한 결과는 외부적 스트레스로 작용하는 자외선에 의해 피부 노화가 촉진되는 이유로서 11β— HSD1의 활성에 의한 스트레스 호르몬의 활성화가 주요 작용 기전으로 설명이 될 수 있음을 시사한다. Intracellular reactions by stress are reactions of glucocorticoids acting as stress hormones and are regulated by secretion of active cortisol and Ιβ β -HSDl (11 β -hydroxysteroid dehydrogenasel) activity. In this case, Ιβ β-HSDl converts inactive glucocorticoids into active glucocorticoids, thereby playing an important role in regulating the concentration of cellular agents and activating corticosteroid receptors in target tissues. Recently, an interesting paper on Ιβ β-HSDl in the skin has been published. Experiments with skin tissues in women have shown that with age, the activity of ΙΙ β -HSDl in the skin increases, and its expression in fibroblasts. (Tiganescu A et al, 2013; 123 (7): 3051-3060). In addition, A significant increase in this enzyme was found in the dermis when comparing skin tissues before and after menopause. In addition, according to the team's presentation, the comparison of the ΙΙ β -HSDl activity in the areas where photoaging has progressed and in which endogenous aging occurs mainly in human arms shows that the activity of ΙΙβ -HSDl at the sites where photoaging occurs It is reported to be about four times higher than the site where endogenous aging occurs (Tiganescu A et al, 2011; 131, 30-36). These results suggest that the activation of stress hormones by the activity of 11β—HSD1 may be explained as the main mechanism of action as the reason that skin aging is promoted by ultraviolet light acting as external stress.
ΙΙ β -HSDl의 발현 및 활성 저해는 피부 상처 치료 (Tiganescu A et al , 2014； JOE- 13-0420) , 항당뇨 등의 대사 질환 치료 (James S et al , 2013) 등 다양한 생리학적 효과가 보고되고 있다. 그러나, 피부에서의 광노화 억제 효과에 대해서는 연구결과가 미미한 실정이다. Inhibition of the expression and activity of ΙΙ β -HSDl has been reported to have various physiological effects such as the treatment of skin wounds (Tiganescu A et al, 2014; JOE-13-0420) and the treatment of metabolic diseases such as antidiabetics (James S et al, 2013) It is becoming. However, the results of the study on the photoaging inhibitory effect on the skin are insignificant.
이에， 본 발명자들은 상기 종래기술들의 문제점들을 극복하기 위하여 예의 연구노력한 결과， 자외선에 의해 활성된 ΙΙ -HSDl의 역할이 광노화에 관련이 있음을 인지하고 이를 개선하는 물질을 발굴하고자， 항노화에 효능이 있다고 보고된 식물 추출물을 바탕으로 비교， 선별하였으며, 그 중 능실 추출물 또는 그 분획물의 경우， ΙΙ β -HSDl 및 丽 Ps , 염증 인자의 발현과 진피층 두께. 감소를 억제함으로써 피부 노화 억제, 노화 피부의 개선 및 치료할 수 있음을 확인하고， 본 발명을 완성하게 되었다. Accordingly, the present inventors have made diligent research efforts to overcome the problems of the prior art, to discover that the role of ΙΙ-HSDl activated by ultraviolet light is related to photoaging and to find a substance that improves the efficacy of anti-aging Based on the plant extracts reported to have been compared and selected, among them, the extracts of the filth extract or its fractions, ΙΙ β -HSDl and 丽 Ps, the expression of inflammatory factors and the thickness of the dermis . It has been confirmed that the inhibition of skin aging, the improvement and treatment of aging skin can be suppressed, and the present invention has been completed.
【선행기술문헌】 Prior Art Documents
【특허문헌】 [Patent literature]
KR10-0927970 B KR10-0927970 B
【발명의 상세한 설명】 [Detailed Description of the Invention]
【기술적 과제】 [Technical problem]
따라세 본 발명의 주된 목적은 ΙΙβ -HSDl 및 丽 Ps , 염증 인자의 발현 및 진피층 두께 감소를 억제함으로써 피부 노화 억제ᅳ 노화 피부의 개선효과를 갖는
능실 추출물 또는 능실 분획물을 유효성분으로 함유하는 스트레스 자극에 의한 피부노화 억제 또는 개선용 조성물을 제공하는 데 있다. Therefore, the main object of the present invention is to inhibit the skin aging by inhibiting the expression of ΙΙβ -HSDl and 丽 Ps, the expression of inflammatory factors and the thickness of the dermis, which has the effect of improving the aging skin. It is to provide a composition for inhibiting or improving skin aging due to stress stimulation containing a twill extract or a twill fraction as an active ingredient.
본 발명의 다른 목적은 상기 능실 추출물 또는 능실 분획물의 스트레스 자극에 의한 피부노화 억제 또는 개선용 조성물의 제조에 사용되기 위한 용도 또는 그러한 조성물을 이용한 피부노화 억제 또는 개선 방법을 제공하는데 있다. Another object of the present invention is to provide a method for use in the preparation of a composition for inhibiting or improving skin aging due to stress stimulation of the stalk extract or stalk fraction or a method for inhibiting or improving skin aging using such a composition.
【기술적 해결방법】 Technical Solution
본 발명의 한 양태에 따르면， 본 발명은 능실 추출물 또는 능실 분획물을 유효성분으로 함유하는 스트레스 자극에 의한 피부노화 억제 또는 개선용 조성물을 제공한다. According to one aspect of the present invention, the present invention provides a composition for inhibiting or improving skin aging due to stress stimulation, which contains an extract of the stalk extract or the stalk fraction as an active ingredient.
본 발명에 있어서， 상기 조성물은 화장료 또는 피부외용제로 사용되는 것을 특징으로 한다. In the present invention, the composition is characterized in that it is used as a cosmetic or skin external preparation.
능실은 물에 떠서 자라는 한해살이 풀로 길쭉한 줄기를 가지고 있으며 마디마다 깃털 모양으로 갈라진 물속뿌리를 형성하여 떠다닌다. 이러한 능실은 자양， 강장의 효능이 있어 신체가 허약한 사람에게 좋은 영양제가 되며 해독과 지갈 작용을 하여 주독도 풀어준다고 알려져 있다. 또한， 한국 등록특허 10- 0927970호에는 능실 추출물이 피지분비억제 및 여드름 완화효과가 있다고 공지하고 있다. 그러나， 능실 추출물이 스트레스 자극에 의한 피부 광노화에 효과가 있다는 사실은 어디에도 공지되어 있지 않다. 이에， 본 발명자들은 능실 추출물이 스트레스 자극, 특히 자외선에 의한 스트레스 자극에 의한 피부 광노화를 억제하는 효과가 있는 것을 발견하고 본 발명을 완성하게 되었다. Thunsil is a yearly grass that grows in water and has elongated stems. Each node floats in the shape of a feather-shaped water root. This insufficiency is effective in nourishing and tonic, so the body is a good nutritional to the weak, it is known to detoxify and act as a detoxification. In addition, Korean Patent No. 10-0927970 discloses that the extract of twill is effective in inhibiting sebum secretion and acne. However, it is not known anywhere that the extract of twill has an effect on skin photoaging caused by stress stimulation. Accordingly, the present inventors have found that the twill extract has an effect of suppressing skin photoaging due to stress stimulation, in particular, stress stimulation by ultraviolet rays, and thus, the present invention has been completed.
본 발명의 상기 용어 '스트레스 자극' 은 외부환경에서 주는 유해한 자극이 피부에서 스트레스 호르몬 (글루코코르티코이드)을 증가시켜 피부 노화 또는 피부 위축 등을 유발하는 것을 말한다. 본 발명에서는 구체적으로 자외선에 의한 스트레스 자극에 의한 것을 의미한다. The term 'stress stimulus' of the present invention means that harmful stimuli from the external environment increase the stress hormone (glucocorticoid) in the skin and cause skin aging or skin atrophy. In the present invention, it means specifically by stress stimulation by ultraviolet rays.
본 발명에 있어서， 상기 피부노화는 자외선에 의한 광노화 (Photoaging)일 수 있으며, 더욱. 바람직하게는 UVB Jl travi olet B)에 의한 광노화인 것을 특징으로 한다.
본 발명의 상기 용어 '광노화 (Phhtoagipg) ' 는 외부 환경적인 요인에 의해 유발되는 현상으로， 가장 대표정인 인자로는 자외선이 있다. 이 자외선은 단백질 분해효소의 활성화와 기질단백질의 사슬절단 및 비정상적인 교차결합 등의 생체 구성 성분들의 손상을 가져오고， 이러한 메커니즘의 반복은 외관상으로도 확연한 피부노화를 초래하게 된다. 즉， 본 발명에서는 외부환경과는 무관하게 유전적 요소에 의해 발생하는 내인성 노화와는 달리， 상기와 같이 자외선에 의한 광노화로 인해 발생하는 피부노화를 억제 또는 개선하기 위한 조성물， 특히 화장료 조성물， 또는 피부 외용제 조성물에 관한 것이다. In the present invention, the skin aging may be photoaging by ultraviolet rays, moreover. Preferably it is characterized by photoaging by UVB Jl travi olet B). The term 'photo-aging (Phhtoagipg)' of the present invention is a phenomenon caused by external environmental factors, and the most representative factor is ultraviolet rays. This ultraviolet light causes damage to biological components such as protease activation, substrate protein chain breakdown and abnormal crosslinking, and the repetition of this mechanism leads to apparent skin aging. That is, in the present invention, unlike endogenous aging caused by genetic factors regardless of the external environment, a composition for inhibiting or improving skin aging caused by photoaging caused by ultraviolet rays, in particular a cosmetic composition, or It relates to an external preparation composition for skin.
본 발명에 있어서， 상기 능실 추출물은 종래에 사용되어진 어떠한 용매로도 추출될 수. 있으며， 바람직하게는 물， 탄소수 1 내지 4의 저급 알코을， 탄소수 3 내지 6의 다가알코올, 글리세린， 프로필렌 글리콜 또는 부틸렌 글리콜로 구성된 군에서 선택된 하나 이상의 용매로 추출하는 것을 특징으로 한다. In the present invention, the twill extract can be extracted with any solvent conventionally used . Preferably, water, lower alcohol having 1 to 4 carbon atoms, polyhydric alcohol having 3 to 6 carbon atoms, glycerin, propylene glycol or butylene glycol is characterized in that the extraction with one or more solvents selected from the group consisting of.
상기 추출용매를 이용한 추출방법으로는 통상적인 식물의 추출방법 예를 들면， 열수 추출, 환류냉각 추출, 초음파 추출， 초임계 추출 등의 방법을 사용할 수 있으며, 구체적으로는 분쇄 또는 파쇄에 의한 분말을 상기한 추출 용매 증에 침적하여 3시간 동안 초음파 추출 및 이의 3회 반복 혹은 24 ~ 72시간 동안 실온 추출하였다. As an extraction method using the extracting solvent, a conventional plant extraction method may be used, for example, hot water extraction, reflux cooling extraction, ultrasonic extraction, supercritical extraction, or the like. It was immersed in the above extraction solvent and sonicated for 3 hours and repeated three times or room temperature for 24 to 72 hours.
본 발명에 있어서， 상기 능실 분획물은 능실 추출물을 종래의 계통적 분획방법에 사용 되어진 어떠한 용매로도 분획화할 수 있으며, 바람직하게는 저극성 유기용매로 더욱 바람직하게는 핵산， 메틸렌 클로라이드， 에틸아세테이트 또는 n-부탄올로 구성된 군에서 선택된 하나 이상의 용매로 분획화하는 것을 특징으로 한다. In the present invention, the lysyl fraction can be fractionated by any solvent used in the conventional systematic fractionation method, preferably a low polar organic solvent, more preferably nucleic acid, methylene chloride, ethyl acetate or n -Fractionate with at least one solvent selected from the group consisting of butanol.
본 발명에 있어서, 상기 능실 추출물 또는 능실 분획물은 그대로 사용할 수도 있으나 여과 후 농축한 액스 형태 또는 동결 건조하여 동결건조물 형태로 사용가능 한 것을 특징으로 한다. In the present invention, the twill extract or the twill fraction may be used as it is, characterized in that it can be used in the form of a concentrated lyophilized or lyophilized after filtration.
본 발명에 있어서， 상기 피부노화는 11베타-에이치에스디 1( 11 β _
hydroxysteroid dehydrogenasel) 발현을 억제함으로써 피부노화를 억제 또는 개선시키는 것을 특징으로 한다. In the present invention, the skin aging is 11 beta-HSD 1 (11 β _ It is characterized by inhibiting or improving skin aging by inhibiting the expression of hydroxysteroid dehydrogenasel).
11베타-에이치에스디 1(11 β— hydroxysteroid dehydrogenasel , ΙΙβ-HSDl)은 스트레스 호르몬으로 작용하는 글루코코르티코이드의 반웅을 조절한다. 최근 논문에 따르면 이러한 ΙΙβ-HSDl은 나이가 들어감에 따라 피부에서 ΙΙβ-HSDl 활성이 증가한다고 보고하고 있다 (Tiganescu A et al , 2013； 123(7) :3051-3060) . 또한， 본 연구팀의 광노화와 내인성 노화가 진행되는 각각의 부위에서 ΙΙβ-HSDl 활성 정도를 비교한 결과, 광노화가 일어나는 부위에서의 ΙΙβ-HSDl의 활성도가 내인성 노화가 일어나는 부위에 비해 약 4배 이상 높다고 보고하였다 (Tiganescu A et al, 2011 ;131， 30-36). 이러한 ΙΙβ-HSDl의 발현 및 활성 저해는 피부 상처 치료 (Tiganescu A et al， 2014； JOE- 13-0420) , 항당뇨 등의 대사 질환 치료 (James S et al , 2013) 등 다양한 생리학적 효과가 보고되고 있다. 그러나， 피부에서의 광노화 억제 효과에 대해서는 연구결과가 미미한 실정이다. 11beta-HSD1 (11β-hydroxysteroid dehydrogenasel, ΙΙβ-HSDl) regulates the reaction of glucocorticoids to act as stress hormones. Recent papers report that ΙΙβ-HSDl increases ÎΙβ-HSDl activity in the skin with age (Tiganescu A et al, 2013; 123 (7): 3051-3060). In addition, comparing the degree of ΙΙβ-HSDl activity at each site where photoaging and endogenous aging progressed, the researchers found that the activity of ΙΙβ-HSDl at the site where photoaging occurred was about 4 times higher than the site where endogenous aging occurred. Reported (Tiganescu A et al, 2011; 131, 30-36). Inhibition of the expression and activity of ΙΙβ-HSDl has been reported by various physiological effects such as skin wound treatment (Tiganescu A et al, 2014; JOE-13-0420), metabolic diseases such as antidiabetic treatment (James S et al, 2013). It is becoming. However, the results of the study on the photoaging inhibitory effect on the skin are insignificant.
본 발명의 실험예에 따르면， 자외선에 의해 과발현된 ΙΙβ-HSDl의 경우, 상기 능실 추출물과 분획물을 처리한 결과, 발현이 현저하게 억제되는 것을 확인하였다. 이러한 결과로 볼 때, 상기 추출물과 분획물은 자외선에 의해 증가된 ΙΙβ-HSDl의 발현을 저해함으로써 피부 노화의 억제， 개선 및 치료할 수 있음을 의미한다 (실험예 1 참조). According to the experimental example of the present invention, in the case of the ΙΙβ-HSDl overexpressed by ultraviolet light, as a result of treatment of the extract and fractions, it was confirmed that the expression is significantly suppressed. These results indicate that the extracts and fractions can inhibit, improve and treat skin aging by inhibiting the expression of Ιβ-HSDl increased by ultraviolet rays (see Experimental Example 1).
본 발명에 있어서， 상기 피부노화는 廳 Ps 및 염증인자 발현을 억제함으로써 피부노화를 억제 또는 개선시키는 것을 특징으로 한다. In the present invention, the skin aging is characterized by inhibiting or improving skin aging by inhibiting the expression of 廳 Ps and inflammatory factors.
醒 Ps(Matrix metal loproteinases)는 기질단백질을 분해하는 대표적인 효소로 한 번의 자외선 조사에도 피부 내의 醒 P활성이 증가되고ᅵ 피부 내의 콜라겐 및 기타 기질 단백질을 현저하게 분해시켜 피부 노화를 촉진하는데 증요한 요인으로 작용한다. 醒Ps (Matrix metal loproteinases) is increased醒P activity in the skin in a single UV irradiation Representative enzymes that break down matrix proteins and i to to significantly decompose collagen and other matrix proteins in the skin, it promotes skin aging increases important factor Acts as.
본 발명의 실험예에 따르면， 자외선에 의해 과발현된 廳 Ps (醒 P-1, 3, 9) 및 염증인자의 경우， 능실 추출물 및 분획물을 처리한 결과， 발현이 현저하게 억제되는 것을 확인하였다. 이러한 결과로 볼 때， 본 발명의 추출물 및 분획물은 자외선에 의해 증가된 匪 Ps의 발현을 저해함으로써 피부 노화의 억제， 개선 및
치료할 수 있음을 의미한다 (실험예 2 내지 5 참조) . According to the experimental example of the present invention, in the case of 廳 Ps (醒 P-1, 3, 9) and inflammatory factors overexpressed by ultraviolet rays, as a result of treatment of the extract and fractions, it was confirmed that the expression is significantly suppressed. In view of these results, the extracts and fractions of the present invention inhibit the expression of 匪 Ps increased by ultraviolet light, thereby inhibiting, improving and It means that it can be treated (see Experimental Examples 2 to 5).
본 발명에 있어서， 상기 피부노화는 진피층 두께 감소를 억제함으로써 피부노화를 억제 또는 개선시키는 것을 특징으로 한다. In the present invention, the skin aging is characterized in that to suppress or improve the skin aging by inhibiting the reduction of the dermal layer thickness.
본 발명의 실험예에 따르면， 자외선에 의한 광노화 피부 동물모델에 상기한 능실 추출물을 포함한 시료를 처리한 결과, 자외선에 의해 손상된 진피층의 두께가 회복되어 있는 것을 확인 하였다. 이러한 결과로 볼 때， 본 발명의 능실 추출물 또는 분획물이 피부 광노화를 개선， 치료할 수 있다는 것올 의미한다 (실험예 6) . According to the experimental example of the present invention, as a result of treating the sample containing the above-mentioned twill extract in the photo-aging skin animal model by ultraviolet rays, it was confirmed that the thickness of the dermal layer damaged by the ultraviolet rays was recovered. In view of these results, it means that the extract or fraction of the present invention can improve and treat skin photoaging (Experimental Example 6).
본 발명에 있어서， 상기 능실 추출물 또는 능실 분획물은 조성물 총 중량에 대하여 0.01 내지 90 중량 %로 포함되는 것을 특징으로 한다. 상기의 범위를 벗어나는 경우에는 제형화가 용이하지 않아 바람직하지 않다. In the present invention, the twill extract or the twill fraction is characterized in that it comprises 0.01 to 90% by weight relative to the total weight of the composition. If it is outside the above range, the formulation is not easy and is not preferable.
본 발명에 있어서, 상기 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며， 예를 들어 유액， 크림， 화장수， 팩， 파운데아션， 로션, 미용액, 모발화장료 등을 들 수 있다. 구체적으로는， 스킨로션， 스킨소프너， 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스처로션， 영양로션， 맛사지크림， 영양크림, 모이스처크림, 핸드크림， 파운데이션, 에센스， 영양에센스， 팩， 비누， 클렌징 품， 클렌징로션， 클렌징크림， 바디로션 및 바디클렌저의 제형을 포함한다. In the present invention, the composition may be prepared in any formulation commonly prepared in the art, for example, emulsion, cream, lotion, pack, foundation, lotion, essence, hair cosmetics, etc. . Specifically, Skin Lotion, Skin Softener, Skin Toner, Astringent, Lotion, Milk Lotion, Moisture Lotion, Nutrition Lotion, Massage Cream, Nutrition Cream, Moisture Cream, Hand Cream, Foundation, Essence, Nutrition Essence, Pack, Soap, Cleansing Product, cleansing lotion, cleansing cream, body lotion and body cleanser.
본 발명의 화장품 조성물은 담체 이외에 다른 보조제를 포함할 수 있는데， 예를 들면 보존제， 항산화제， 안정화제, 용해화제， 비타민, 안료 및 향료 등을 포함할 수 있다ᅳ Cosmetic compositions of the present invention may include other auxiliaries in addition to the carrier, for example, may include preservatives, antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors.
본 발명에 있어서， 상기 조성물은 각각 통상의 방법에 따라 산제, 과립제， 정제, 캡슐제， 현탁액， 에멀견, 시럽， 에어로졸 등의 외용제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있으며， 바람직하게는 크림, 젤, 패취， 분무제, 연고제, 경고제, 로션제， 리니멘트제 파스타제 또는 카타플라스마제 제형을 가질 수 있다. In the present invention, the composition may be used in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, and other external preparations and sterile injectable solutions, respectively, according to a conventional method. May have a cream, gel, patch, spray, ointment, warning, lotion, liniment pasta or cataplasma formulation.
상기 조성물에 포함될 수 있는 담체， 부형제 및 회석제로는 락토즈, 덱스트로즈， 수크로스, 올리고당， 솔비를, 만니를， 자일리를， 에리스리를ᅳ
말티를， 전분， 아카시아 고무， 알지네이트， 젤라틴， 칼슘 포스페이트, 칼슘 실리케이트， 셀를로즈， 메틸 셀롤로즈, 미정질 셀를로스， 폴리비닐 피롤리돈， 물， 메틸히드록시벤조에이트, 프로필히드록시벤조에이트， 탈크， 마그네슘 스테아레이트 및 광물유를 들 수 있다 . 제제화할 경우에는 보통 사용하는 충진제， 증량제， 결합제， 습윤제， 붕해제， 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제， 산제， 과립제, 캡슐제 등이 포함되며， 이러한 고형제제는 상기 추출물에 적어도 하나 이상의 부형제 예를 들면， 전분, 칼슘카보네이트 (ca l ci um carbonate) , 수크로스 (sucrose) 또는 락토오스 ( l actose) , 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슴 스티레이트 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상제제로는 현탁제， 내용액제, 유제， 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제， 예를 들면 습윤제， 감미제, 방향제， 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액， 비수성용제， 현탁제, 유제， 동결건조제제， 좌제가 포함된다. 비수성용제， 현탁제로는 프로필렌글리콜 (propylene glycol ) , 폴리에틸렌 글리콜， 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위템솔 (wi tepso l ) , 마크로골, 트왼 ( tween) 61， 카카오지， 라우린지， 글리세로제라틴 등이 사용될 수 있다. Carriers, excipients, and diluents that may be included in the composition include lactose, dextrose, sucrose, oligosaccharides, sorbbi, manny, xili, and erythritol. Malty, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, Talc, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like. Such solid preparations may contain at least one excipient such as starch, calcium carbonate, water, or the like. Prepared with a mixture of sucrose or lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium styrate talc are also used. Oral liquid preparations include suspending agents, liquid solutions, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, wi tepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
또한 상기 조성물의 바람직한 투여량은, 환자의 상태 및 체중, 질병의 정도, 약물형태， 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나 바람직한 효과를 위해서， 본 발명의 조성물은 1일 0.0001 내지 100mg/kg으로， 바람직하게는 0.001 내지 10mg/kg으로 투여하는 것이 좋다. 외용투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다. The preferred dosage of the composition also depends on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art. However, for the desired effect, the composition of the present invention is preferably administered at 0.0001 to 100mg / kg, preferably 0.001 to 10mg / kg per day. Topical administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
【유리한 효과】 Advantageous Effects
이상 설명한 바와 같이， 본 발명의 능실 추출물 또는 분획 추출물은 자외선에 의해 과발현된 ΙΙ β -HSDl , MMPs 및 염증인자의 발현을 억제하고
자외선에 의해 손상을 입은 피부에서 진피 두께 감소를 억제시킴으로써 자외선과 같은 스트레스에 의한 피부노화를 억제, 개선 및 치료할 수 있는 우수한 효과를 나타낸다. As described above, the filth extract or fraction extract of the present invention inhibits the expression of ΙΙ β -HSDl, MMPs and inflammatory factors overexpressed by UV light. By suppressing the decrease in the thickness of the dermis in the skin damaged by ultraviolet rays, it shows an excellent effect of inhibiting, improving and treating skin aging caused by stress such as ultraviolet rays.
【도면의 간단한 설명】 [Brief Description of Drawings]
도면 1은 사람 섬유아세포에 능실 추출물과 분획물 처리 시 ΙΙ β -HSDl 단백'질 발현에 미치는 영향을 측정한 실험예 1의 결과에 대한 그림이다. Figure 1 is a picture of the results of Experimental Example 1 measuring the effect on the expression of ΙΙ β -HSDl protein 'in the treatment of the extract and fractions in human fibroblasts.
도면 2는 사람 섬유아세포에 능실 추출물과 분획물 처리 시 醒 P-1 단백질 발현에 미치는 영향을 측정한 실험예 2의 결과에 대한 그래프이다. Figure 2 is a graph of the results of Experimental Example 2 measuring the effect on the P-1 protein expression in the treatment of the extract and fractions in human fibroblasts.
도면 3은 사람 섬유아세포에 능실 추출물과 분획물 처리 시 匪 P-3 메신저 RNA 발현에 미치는 영향을 측정한 실험예 3의 결과에 대한 그래프이다. Figure 3 is a graph of the results of Experimental Example 3 measuring the effect on 匪 P-3 messenger RNA expression in the treatment of the extract and fractions in human fibroblasts.
도면 4는 사람 섬유아세포에 능실 추출물과 분획물 처리 시 fflP-9 메신저 R A 발현에 미치는 영향을 측정한 실험예 3의 결과에 대한 그래프이디- . 4 is a graph showing the results of Experimental Example 3, which measured the effect of fflP-9 messenger R A expression upon treatment of filth extract and fraction on human fibroblasts.
도면 5는 사람 각질형성세포에 능실 추출물과 분획물 처리 시 C0X-2 메신저 RNA 발현에 미치는 영향을 측정한 실험예 4의 결과에 대한 그래프이다. 도면 6은 사람 각질형성세포에 능실 추출물과 분획물 처리 시 iNOS 메신저 R A 발현에 미치는 영향을 측정한 실험예 4의 결과에 대한 그래프이다. Figure 5 is a graph of the results of Experimental Example 4 measuring the effect on the C0X-2 messenger RNA expression when treatment with the extract and fractions in human keratinocytes. Figure 6 is a graph of the results of Experimental Example 4 measuring the effect on the expression of iNOS messenger R A in the treatment of extracts and fractions in human keratinocytes.
도면 7은 삼차원 인공피부에 능실 추출물과 분획물 처리 시 匪 P-1 단백질 발현에 미치는 영향을 측정한 실험예 5의 결과에 대한 그래프이다. Figure 7 is a graph of the results of Experimental Example 5 measuring the effect on the P-1 protein expression in the treatment of the extract and fractions in the three-dimensional artificial skin.
도면 8은 광노화 피부 동물모델에 능실 추출물을 포함한 시료 처리 시 진피층의 두께의 변화에 미치는 영향을 측정한 실험예 6의 결과에 대한 그래프이다. Figure 8 is a graph of the results of Experimental Example 6 measuring the effect on the change in the thickness of the dermis layer during the treatment of the sample containing the twill extract in the photo-aging skin animal model.
【발명의 실시를 위한 형태】 [Form for implementation of invention]
이하 본 발명을 하기 예에 의해 상세히 설명한다. 다만 하기 예는 본 발명을 예시하기 위한 것일 뿐, 하기 예에 의해 본 발명의 범위가 제한되는 것은 아니다.
실시예 l: 능실-메탄올 추출물의 제조 Hereinafter, the present invention will be described in detail by the following examples. However, the following examples are only for illustrating the present invention, and the scope of the present invention is not limited by the following examples. Example l Preparation of Tungsyl-Methanol Extract
본 발명에서 사용된 능실은 대한민국 서울 경동시장의 한약재상에서 구입하여 사용하였다. Tungsil used in the present invention was purchased from the herbal medicine of Gyeongdong market, Seoul, Korea.
능실 100g을 메탄을 1L에 담구어 3시간 동안 초음파 추출하였다. 이를 3회 반복하여 얻은 추출액을 감압 건조하여 농축하여 농축물 26.5 g을 얻었다. 실시예 2: 능실 분획의 제조 100 g of twill was soaked in 1 L of methane and sonicated for 3 hours. The extraction was repeated three times. The extract was dried under reduced pressure and concentrated to give 26.5 g of concentrate. Example 2: Preparation of the Twill Fraction
위 실시예 1에서 제조한 능실-메탄을 추출물 100g을 500ml의 증류수에 현탁 시키고 계통학적 분획방법에 따라 동량의 메틸렌 클로라이드 (methylene chloride), EtOAc , n-BuOH로 각각 3회씩 추출하여 분획한 후 감압 농축하여 메틸렌 클로라이드층， EtOAc층， n-BuOH층 물층을 획득하여 각 MC분획， E분획, Bu분획으로 하였다. 실험예 1: 능실 추출물과 분획물의 ΙΙβ-HSDl 저해능 실험 100 g of the extract of tungsyl-methane prepared in Example 1 was suspended in 500 ml of distilled water, and extracted and extracted three times each with the same amount of methylene chloride, EtOAc, and n-BuOH according to the systematic fractionation method. Concentrated to obtain a methylene chloride layer, EtOAc layer, n-BuOH layer water layer to each MC fraction, E fraction, Bu fraction. Experimental Example 1: Experiment of ΙΙβ-HSDl Inhibitory Activity of Extracts and Fractions of Twill
실시예 1 및 2에 대하여 먼저 사람 섬유아세포에서 능실 추출물과 분획물의 UVB로 유도된 ΙΙβ-HSDl 저해 효과를 확인하기 위해 사람 섬유아세포를 6 well 세포 배양 접시에 4xl05의 밀도로 접종한 후 37°C， 5% C02 배양기에서 24시간 배양하였다. UVB를 15mJ 조사한 후 각 추출물을 첨가하여 72 시간 동안 배양하고， ΙΟΟμιη의 lysis 버퍼를 첨가한 후 단백질을 추출하고 브래드포드 에세이 (Bradford assay)를 통해 595nm에서 단백질을 정량하였다. SDS-PAGE ( Sod i umdodecy 1 su 1 f at e-po 1 yacry 1 am i de gel electrophoresis)를 이용하여 전기영동하고 PVDF (Polyvinyl idene fluoride, Bio-rad, 미국)에 단백질 밴드를 전달하여 ECL (Enhanced chemi luminescence, ThermoScient i f ic , 미국) 용액으로 단백질 발현량을 확인하였다. In Examples 1 and 2, in order to confirm the UVB-induced ΙΙβ-HSDl inhibitory effect of the stalk extract and fractions in human fibroblasts, human fibroblasts were inoculated at a density of 4xl0 5 in a 6 well cell culture dish at 37 ° C. C, 5% C0 2 incubator was incubated for 24 hours. UVB was irradiated with 15mJ, and each extract was incubated for 72 hours, ΙΟΟμιη lysis buffer was added, the protein was extracted, and the protein was quantitated at 595 nm by a Bradford assay. Electrophoresis using SDS-PAGE (Sod i umdodecy 1 su 1 f at e-po 1 yacry 1 am i de gel electrophoresis) and transfer protein bands to PVDF (Polyvinyl idene fluoride, Bio-rad, USA) Enhanced chemi luminescence, ThermoScient if ic, USA) solution was confirmed the amount of protein expression.
그 결과， 도면 1에 나타낸 바와 같이 메틸렌 클로라이드 분획을 제외한 능실 추출물 및 분획물에서 ΙΙβ-HSDl의 저해 효능올 확인하였다. 도면에서 능실 Μ은 능실추출물， 능실 MC는 능실 MC methylene chloride)분획， 능실 E는 능실 E(EtOAc)분획， 능실 B는 능실 Bu(n-BuOH)분획을 의미한다.
실험예 2: 능실 분획물의 MMP-1 저해능 심험 As a result, as shown in Figure 1 was confirmed the inhibitory effect of Ιββ-HSDl in the extracts and fractions except the methylene chloride fraction. In the figure, the sill Μ means the stalk extract, the stalk MC is the stalk MC methylene chloride) fraction, the stiffness E is the spool E (EtOAc) fraction, and the stiffness B is the stiff Bu (n-BuOH) fraction. Experimental Example 2: MMP-1 Inhibitory Activity of the Twill Fraction
실시예 1 및 2에 대하여 상기의 실험예 1에 기술한 방법과 동일한 방법으로 사람 섬유아세포를 배양하여 UVB 및 각 실시예 2를 첨가한 후 72 시간 추가 배양하여 圆 P-1의 단백질 발현양을 확인하였다. In Example 1 and 2, human fibroblasts were cultured in the same manner as described in Experimental Example 1 above, UVB and each Example 2 were added, followed by 72 hours of incubation to increase the amount of protein expression of P-1. Confirmed.
그 결과， 도면 2에 나타낸 바와 같이， 메틸렌 클로라이드 분획을 제외한 능실 추출물 및 분획물에서 讓 P-1의 저해 효능을 확인하였다. 실험예 3: 능실 분획물의 MMP-3, 9 저해능 실험 As a result, as shown in Figure 2, it was confirmed the inhibitory effect of 讓 P-1 in the extracts and fractions except the methylene chloride fraction. Experimental Example 3: MMP-3, 9 Inhibitory Activity of the Twill Fraction
丽 P— 1과 다른 기질 단백질을 분해하는 효소로서의 醒 P-3, 9의 저해효능을 평가하기 위해 실시예 1 추출물 및 실시예 2의 분획물을 처리하여 메신저 R A 발현양을 알아보았다. In order to evaluate the inhibitory effect of P-3, 9 as an enzyme that degrades P-1 and other matrix proteins, the extracts of Example 1 and fractions of Example 2 were treated to determine the amount of messenger R A expression.
상기의 실험예 1에 기술한 방법과 동일한 방법으로 사람 섬유아세포를 배양하여 6 well 접시에 세포를 접종하여 24 시간 뒤 UVB 15mJ을 조사한 후 각 추출물을 첨가하였다. 24 시간 추가 배양한 후 세포에 트리졸 (RNA iso, DAKARA, 일본) 1 m을 첨가하여 RNA를 분리하였다. 자외선 검출기를 이용하여 260nm에서 RNA를 정량한 후， cDNA를 합성하였다 (Reverse Transcriptase Mix, ELPIS biotech, 한국). RT-PCR은 PCR 기계 (Step One Plus, Applied Biosystems, 미국)을 이용하였고 사이버그린 (SYBRGreen supermix, Applied Biosystems, 미국)을 丽 P- 3와 匪 P-9 프라이머 및 cDNA와 함께 첨가하여 에세이하였다. 프라이머와 반웅 조건은 하기의 표 1과 같았으며， 匪 P-3과 醒 P-9의 발현양은 β-actin 유전자에 대해 보정을 하여 나타내었다. Human fibroblasts were cultured in the same manner as described in Experimental Example 1 above, the cells were inoculated into 6 well plates and irradiated with UVB 15mJ after 24 hours, and then each extract was added. After further incubation for 24 hours, RNA was isolated by adding 1 m of trizol (RNA iso, DAKARA, Japan) to the cells. After quantifying RNA at 260nm using an ultraviolet detector, cDNA was synthesized (Reverse Transcriptase Mix, ELPIS biotech, Korea). RT-PCR was performed using a PCR machine (Step One Plus, Applied Biosystems, USA) and assayed by the addition of cyberrin (SYBRGreen supermix, Applied Biosystems, USA) with P-3 and P-9 primers and cDNA. The primer and reaction conditions were shown in Table 1 below, and the expression levels of 匪 P-3 and 醒 P-9 were expressed by correcting the β-actin gene.
그 결과， 도면 3과 도면 4에 나타낸 바와 같이， 능실 추출물 및 메틸렌 클로라이드， 에틸 아세테이트， n-부탄올 분획물에서 匪 P-3, 9 발현 저해능올 확인하였다. As a result, as shown in Figures 3 and 4, the 능 P-3, 9 expression inhibitory activity was confirmed in the extracts of the twill and methylene chloride, ethyl acetate, n-butanol.
【표 11 Table 11
프라이머 서열 반응 조건 Primer Sequence Reaction Conditions
3-actin Forward 5-GGCCATCTCTTGCTCGAAGT-3' 94'C에서 5분 동안
Reverse 5'-GAGACCTTCAACACCCCAGC-3' 중합효소 활성호卜, 95 °C3-actin Forward 5-GGCCATCTCTTGCTCGAAGT-3 'for 5 minutes at 94'C Reverse 5'-GAGACCTTCAACACCCCAGC-3 'Polymerase Activator, 95 ° C
Forward 5'-ATTCCATGGAGCCAGGCTTTC-3' 30초, 50 °C 1 분 , 72 °C MP-3 Forward 5'-ATTCCATGGAGCCAGGCTTTC-3 '30 seconds, 50 ° C 1 minute, 72 ° C MP-3
Reverse 5'-CATTTGGGTCAAACTCCAACTGTG-3' 1분간 40 사이클로 βμ바 Reverse 5'-CATTTGGGTCAAACTCCAACTGTG-3 'βμbar at 40 cycles for 1 minute
Forward 5'-GCATACTTGTACCGCTATGG-3' ι_!으 Forward 5'-GCATACTTGTACCGCTATGG-3 'ι_!
MMP-9 MMP-9
Reverse 5'-TATGATGTTATGATGGTCCC-3' Reverse 5'-TATGATGTTATGATGGTCCC-3 '
Forward 5'-TGAGCATCTACGGTTTGCTG-3' Forward 5'-TGAGCATCTACGGTTTGCTG-3 '
COX一 2 COX 一 2
Reverse 5 -TGCTTGTCTGGAACAACTGC-3' Reverse 5 -TGCTTGTCTGGAACAACTGC-3 '
Forward 5 -CATGCTACTGGAGGTGGGTG-3' Forward 5 -CATGCTACTGGAGGTGGGTG-3 '
iNOS iNOS
Reverse 5'-CATTGATCTCCGTGACAGCC-3' 실험예 4 : 능실 추출물과 분획물의 광노화 관련 염증인자 발현 저해능 실험 Reverse 5'-CATTGATCTCCGTGACAGCC-3 'Experimental Example 4: Inhibitory Activity of Inflammatory Factor Expression of Twill Extracts and Fractions Related to Photoaging
광노화 관련 염증인자 발현 저해능을 확인하기 위해 실시예 1 및 실시예 2의 시료를 처리하여 메신져 RNA 발현 정도를 평가하였다. In order to confirm the photo-aging-related inflammatory factor expression inhibition ability, the samples of Examples 1 and 2 were processed to evaluate the messenger RNA expression.
상기의 실험예 3에 기술한 방법과 동일한 방법으로 사람 각질형성세포를 배양하여 6 we l l 접시에 세포를 접종하여 24 시간 뒤 UVB 15mJ을 조사한 후 각 추출물을 첨가하였다. 24시간 추가 배양한 후 상기 실험예 2 동일한 방법으로 real-t ime RT-PCR 하여 염증 유발 인자인 C0X-2(Cyc looxygenase_2)와 iNOS ( inducibl e NO synthase)의 메신저 RNA 발현양을 측정하였다. Human keratinocytes were cultured in the same manner as described in Experimental Example 3 above, the cells were inoculated into 6 we ll plates and irradiated with UVB 15mJ after 24 hours, and then each extract was added. After further incubation for 24 hours, real-t ime RT-PCR was carried out in the same manner as in Experiment 2 to measure messenger RNA expression levels of inflammatory factors C0X-2 ( C yc looxygenase_2) and iNOS (inducibl e NO synthase).
그 결과， 도면 5와 도면 6에 나타낸 바와 같이 실시예 1 및 실시예 2의 시료에 의한 높은 저해능을 확인하였다. 실험예 5 : 삼차원 인공피부 조직에서 능실 추출물의 MMP— 1 저해능 실험 실시예 1의 능실 추출물의 丽 P-1 발현 저해 효과를 in vivo 모델에서 평가하기 위해 삼차원 인공피부 조직을 이용하여 확인하였다. As a result, as shown in FIG. 5 and FIG. 6, the high inhibitory ability by the sample of Example 1 and Example 2 was confirmed. Experimental Example 5: MMP-1 Inhibitory Activity of Twill Extract in Three-Dimensional Skin Tissues In order to evaluate the inhibitory effect of P-1 expression of the twill extract of Example 1 on the in vivo model, it was confirmed using three-dimensional artificial skin tissue.
Epi dermal t i ssue (Skin Ethi cs , Nikoderm Research Inc . , 프랑스)를 growth medi a에 24시간 동안 안정화한 후 UVB 40mJ을 조사한 후 배지에 능실 추출물을 첨가하였다. 72시간 동안 배양 후 해당 배지를 회수하여 상기의 醒 P- 1의 단백질 분비량을 정량 하기 위해 효소결합 면역흡착 분석법 (enzyme- l inked
immunosorbent assay , ELISA)을 수행하였다. Epi dermal ti ssue (Skin Ethi cs, Nikoderm Research Inc., France) was stabilized in growth medi a for 24 hours, and then irradiated with UVB 40mJ. Enzyme-linked immunosorbent assay (enzyme- l inked) to quantify the amount of protein secretion of 醒 P-1 after incubation for 72 hours An immunosorbent assay (ELISA) was performed.
그 결과， 도면 7에 나타낸 바와 같이 자외선에 의해 과발현된 讓 능실 추출물에 농도 의존적으로 저해됨을 확인하였다. 실험예 6 : 광노화 피부 동물모델에 대한 in vivo 실험 As a result, as shown in Figure 7, it was confirmed that the concentration-dependent inhibition of the over-expression 讓 twill extract by ultraviolet rays. Experimental Example 6: in vivo experiment on the photo-aging skin animal model
실시예 1의 능실 추출물을 포함한 시료가 광노화 피부 동물모델에 미치는 영향을 평가하였다. 1주일에 3회씩 총 8주간 자외선을 조사한 무모쥐 (hai r less mi ce)에 능실 메탄올 추출물을 포함한 시료를 기제에 흔합하여 1일에 2회씩 총 8주간 도포하여 진피 두께를 측정하였다. 기제는 PG (프로필렌 글리콜) : EtOH (에탄을)을 7 : 3으로 흔합하여 sham l ight와 함께 처리하여 대조군으로 사용하였다. The effect of the sample containing the twill extract of Example 1 on the photoaging skin animal model was evaluated. Dermal mice were irradiated with ultraviolet rays three times a week for a total of eight weeks, and the samples containing the twill methanol extract were mixed with the base and applied twice a day for a total of eight weeks to measure dermal thickness. The base was mixed with PG (propylene glycol): EtOH (ethane) at 7: 3 and treated with sham light to serve as a control.
그 결과， 도면 8에 나타낸 바와 같이 자외선에 의해 감소한 진피층의 두께가 능실 추출물을 포함한 시료를 처리함에 따라 희복되는 것을 확인하였다. 제형예 1 : 토너제의 제조 As a result, as shown in FIG. 8, it was confirmed that the thickness of the dermis layer reduced by the ultraviolet rays was leaned as the sample containing the extract of the twill was treated. Formulation Example 1 Preparation of Toner
상기 실시예 1에서 얻은 추출물을 함유하는 토너제를 하기의 표 2에 나타낸 조성 성분 및 조성비에 따라 통상적인 방법으로 제조하였다. The toner agent containing the extract obtained in Example 1 was prepared in a conventional manner according to the composition components and composition ratios shown in Table 2 below.
【표 2】 Table 2
성 분 ingredient
실시예 1 -1 1 .0 Example 1 -1 1.0
글리세린 3.0 Glycerin 3.0
부틸렌 글리클 . 2.0 Butylene Glycle. 2.0
풀리옥시에칠렌 (60) 경화 피마자유 0.5 Fullyoxyethylene 60 Cured Castor Oil 0.5
풀리솔패비트 80 0.5 Pulley Solvent Bit 80 0.5
에탄올 1 0.0 Ethanol 1 0.0
방부제 미량 Preservative traces
향료 미량 A small amount of spices
정제수 잔량
제형예 2 : 로션제의 제조 Purified water level Formulation Example 2: Preparation of Lotion
상기 실시예 1에서 얻은 추출물을 함유하는 로션제를 하기의 나타낸 조성 성분 및 조성비에 따라 통상적인 방법으로 제조하였다. The lotion containing the extract obtained in Example 1 was prepared in a conventional manner according to the composition components and composition ratios shown below.
【표 3】 Table 3
상기 실시예 1에서 얻은 추출물을 함유하는 크림제를 하기의 나타낸 조성 성분 및 조성비에 따라 통상적인 방법으로 제조하였다. The cream containing the extract obtained in Example 1 was prepared in a conventional manner according to the composition components and composition ratios shown below.
【표 4】 Table 4
함량 (중량 %) 실시예 1一 1 1 .0
글리세릴스테아레이트 /피이지 -1 00스테아레이트 2.0 풀리솔베이트 60 0.5 Content (% by weight) Example 1 一 1 1.0 Glyceryl Stearate / Sebum -1 00 Stearate 2.0 Fully Solate 60 0.5
소르비탄 스테아레이트 0.5 Sorbitan Stearate 0.5
피토스쿠알란 5.0 Phytoscualan 5.0
호호바 오일 3.0 Jojoba Oil 3.0
카프릴릭 /카프릭트리글리세라이드 1 0.0 Caprylic / Caprictriglyceride 1 0.0
알로에 버터 3.0 Aloe Butter 3.0
밀납 1 .0 Beeswax 1.0
스테아릴 알코올 0.5 Stearyl Alcohol 0.5
베해릴 알코올 0.5 Beharyl Alcohol 0.5
스테아린산 0.5 Stearic Acid 0.5
글리세린 7.0 Glycerin 7.0
부릴렌 글리콜 5.0 Burylene Glycol 5.0
카르복시 비닐풀리머 0.2 Carboxy Vinyl Puller 0.2
아르기닌 0.3 Arginine 0.3
디메치콘 ■ 0.5 Dimethicone ■ 0.5
방부제 미량 Preservative traces
향료 미량 A small amount of spices
정제수 잔량 이상의 설명으로부터， 본 발명이 속하는 기술분야의 당업자는 본 발명이 그 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 이와 관련하여， 이상에서 기술한 실시 예들은 모든 면에서 예시적인 것이며 한정적인 것이 아닌 것으로서 이해해야만 한다. 본 발명의 범위는 상기 상세한 설명보다는 후술하는 특허 청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.
Purified water residual amount From the above description, those skilled in the art will understand that the present invention can be implemented in other specific forms without changing the technical spirit or essential features. In this regard, the above-described embodiments are to be understood as illustrative in all respects and not as restrictive. The scope of the present invention should be construed that all changes or modifications derived from the meaning and scope of the following claims and equivalent concepts rather than the detailed description are included in the scope of the present invention.
Claims
【청구항 1】 【Claim 1】
능실 추출물 또는 능실 분획물을 유효성분으로 함유하는 스트레스 자극에 의한 피부노화 억제 또는 개선용 조성물. A composition for suppressing or improving skin aging caused by stress stimulation, containing a neungsil extract or a neungsil fraction as an active ingredient.
【청구항 2】 【Claim 2】
제 1항에 있어서， 상기 조성물은 화장료 또는 피부외용제로 사용되는 것을 특징으로 하는 조성물. The composition according to claim 1, wherein the composition is used as a cosmetic or external skin agent.
【청구항 3】 【Claim 3】
제 1항에 있어서， 상기 피부노화는 자외선에 의한 광노화 (Photoaging)인 것을 특징으로 하는 조성물. ' The composition according to claim 1, wherein the skin aging is photoaging by ultraviolet rays. '
【청구항 4】 【Claim 4】
제 1항에 있어서， 상기 능실 추출물은 물， 탄소수 1 내지 4의 저급 알코을， 탄소수 3 내지 6의 다가알코올， 글리세린， 프로필렌 글리콜 또는 부틸렌 글리콜로 구성된 군에서 선택된 하나 이상의 용매로 추출하는 것을 특징으로 하는 조성물. The method of claim 1, wherein the fennel extract is extracted with one or more solvents selected from the group consisting of water, lower alcohols having 1 to 4 carbon atoms, polyhydric alcohols having 3 to 6 carbon atoms, glycerin, propylene glycol, or butylene glycol. composition.
【청구항 5] [Claim 5]
제 1항에 있어서， 상기 능실 분획물은 능실 추출물을 핵산, 메틸렌 클로라이드， 에틸아세테이트 또는 n-부탄올로 구성된 군에서 선택된 하나 이상의 용매로 분획화하는 것을 특징으로 하는 조성롤. The composition roll according to claim 1, wherein the neungsil fraction is fractionated with one or more solvents selected from the group consisting of nucleic acid, methylene chloride, ethyl acetate, or n-butanol.
【청구항 6】 【Claim 6】
제 1항에 있어서， 상기 능실 추출물 또는 능실 분획물은 농축한 엑스 형태 또는 동결건조 형태로 사용가능 한 것을 특징으로 하는 조성물.
The composition according to claim 1, wherein the neungsil extract or neungsil fraction can be used in the form of concentrated extract or freeze-dried form.
[청구항 7】 [Claim 7]
제 1항에 있어서, 상기 능실 추출물 또는 능실 분획물은 조성물 총 중량에 대하여 0.01 내지 90 증량 %로 포함되는 것을 특징으로 하는 조성물 The composition according to claim 1, wherein the nettle extract or nettle fraction is contained in an amount of 0.01 to 90% by weight based on the total weight of the composition.
【청구항 8】 【Claim 8】
제 2항에 있어서 , 상기 화장료 조성물은 스킨로션， 스킨소프너 , 스킨토너, 아스트린젠트， 로션， 밀크로션， 모이스처로션， 영양로션， 맛사지크림 , 영양크림， 모이스처크림， 핸드크림， 파운데이션, 에센스， 영양에센스, 팩, 비누， 클렌징 품 클렌징로션， 클렌징크림， 바디로션 및 바디클렌저로 구성된 군에서 선택된 제형을 갖는 것을 특징으로 하는 조성물. The method of claim 2, wherein the cosmetic composition includes skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutritional lotion, massage cream, nutritional cream, moisture cream, hand cream, foundation, essence, nutritional essence. , a composition characterized by having a formulation selected from the group consisting of packs, soaps, cleansing products, cleansing lotions, cleansing creams, body lotions, and body cleansers.
【청구항 9】 【Claim 9】
제 2항에 있어서， 상기 피부외용제 조성물은 크림, 젤, 패취， 분무제， 연고제, 경고제， 로션제, 리니멘트제, 파스타제 및 카타플라스마제로 구성된 군에서 선택된 제형을 갖는 것을 특징으로 하는 조성물.
The composition according to claim 2, wherein the external skin composition has a formulation selected from the group consisting of creams, gels, patches, sprays, ointments, warning agents, lotions, linear agents, pasta agents, and cataplasma agents.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140030820A KR20150108088A (en) | 2014-03-17 | 2014-03-17 | Composition comprising Trapa japonica FLEROV extract for improving or skin-aging stress-induced skin |
| KR10-2014-0030820 | 2014-03-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2015141926A1 true WO2015141926A1 (en) | 2015-09-24 |
Family
ID=54144856
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2014/011418 WO2015141926A1 (en) | 2014-03-17 | 2014-11-26 | Composition for inhibiting or alleviating skin aging caused by stress stimulation, containing trapa japonica as active ingredient |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR20150108088A (en) |
| WO (1) | WO2015141926A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109431846A (en) * | 2018-11-28 | 2019-03-08 | 邯郸学院 | A kind of bioactive ingredients skin care item |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102344703B1 (en) * | 2018-12-28 | 2021-12-30 | 에이앤펩주식회사 | Method of Trapa Natans ferments, a composition for improving skin wrinkles and anti-aging containing the Trapa Natans fermentation product or peptide produced therefrom as an active ingredient and a composition for improving skin aging comprising a fermented product |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100706282B1 (en) * | 2004-05-13 | 2007-04-11 | 학교법인 인제학원 | Composition comprising an extract of Trapa japonica Flerov. showing antioxidative effect |
| KR100927970B1 (en) * | 2007-10-31 | 2009-11-24 | 주식회사 코리아나화장품 | Sebum secretion containing acryl extract as an active ingredient and acne relief cosmetic composition |
| WO2011126295A2 (en) * | 2010-04-06 | 2011-10-13 | (주)아모레퍼시픽 | Wrapping fermentation method using medicinal leaves, and composition for external skin application using same |
| KR101116757B1 (en) * | 2009-01-23 | 2012-03-13 | 한국과학기술연구원 | Novel componds isolated Trapa species and antioxidant activity composition |
| JP2014037399A (en) * | 2012-07-18 | 2014-02-27 | Up Well:Kk | Anti-glycation agent and method for producing the same |
-
2014
- 2014-03-17 KR KR1020140030820A patent/KR20150108088A/en not_active Application Discontinuation
- 2014-11-26 WO PCT/KR2014/011418 patent/WO2015141926A1/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100706282B1 (en) * | 2004-05-13 | 2007-04-11 | 학교법인 인제학원 | Composition comprising an extract of Trapa japonica Flerov. showing antioxidative effect |
| KR100927970B1 (en) * | 2007-10-31 | 2009-11-24 | 주식회사 코리아나화장품 | Sebum secretion containing acryl extract as an active ingredient and acne relief cosmetic composition |
| KR101116757B1 (en) * | 2009-01-23 | 2012-03-13 | 한국과학기술연구원 | Novel componds isolated Trapa species and antioxidant activity composition |
| WO2011126295A2 (en) * | 2010-04-06 | 2011-10-13 | (주)아모레퍼시픽 | Wrapping fermentation method using medicinal leaves, and composition for external skin application using same |
| JP2014037399A (en) * | 2012-07-18 | 2014-02-27 | Up Well:Kk | Anti-glycation agent and method for producing the same |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109431846A (en) * | 2018-11-28 | 2019-03-08 | 邯郸学院 | A kind of bioactive ingredients skin care item |
| CN109431846B (en) * | 2018-11-28 | 2021-09-07 | 邯郸学院 | A skin care product containing bioactive components |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150108088A (en) | 2015-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10849840B2 (en) | Compositions and methods for stimulation MAGP-1 to improve the appearance of skin | |
| KR102126469B1 (en) | Cosmetic Compositions comprising extract of Dendrobium candidum flower extract | |
| US7642062B2 (en) | Compositions and methods of their use for improving the condition and appearance of skin | |
| TW201206494A (en) | Use of Tiliacora triandra in cosmetics and compositions thereof | |
| CN103379910A (en) | Extract of the above-ground portions of gynandropsis gynandra or cleome gynandra, and cosmetic, dermatological or pharmaceutical compositions including same | |
| CN113874044B (en) | Skin composition | |
| TWI423810B (en) | Grifola frondosa extract and composition containing thereof for promoting hyaluronic acid production | |
| WO2015141926A1 (en) | Composition for inhibiting or alleviating skin aging caused by stress stimulation, containing trapa japonica as active ingredient | |
| JP2020502172A (en) | Cosmetic composition containing Chinese herbal extract as active ingredient | |
| JP6338107B2 (en) | Skin barrier function improving agent, intercellular adhesion structure formation promoter, tight junction formation promoter, and TRPV4 gene expression enhancer | |
| KR102612128B1 (en) | A cosmetic composition for hair containing an extract of Spiraea prunifolia | |
| JP2009235044A (en) | ENDOTHELIN-1 mRNA EXPRESSION INHIBITOR, MATRIX METALLOPROTEASE-9 mRNA EXPRESSION INHIBITOR, COLLAGEN PRODUCTION PROMOTER, PROFILAGGRIN PRODUCTION PROMOTER, FILAGGRIN PRODUCTION PROMOTER AND AQUAPORIN 3 mRNA EXPRESSION PROMOTER | |
| KR20100056200A (en) | Cosmetic composition containing extracts of adenophora triphylla var. japonica hara, angelica tenuissima and crude drugs | |
| JP2011102264A (en) | Aromatase activator | |
| KR102124698B1 (en) | Cosmetic composition for improving skin wrinkle or skin aging comprising mixture extract of Chrysanthemum morfiolium, Aloe vera, and Hedera Helix | |
| KR101702621B1 (en) | Anti-inflammatory agent containing phlox subulata extract | |
| KR20140013791A (en) | Functional cosmetic composition comprising ginsenosides rh2 and rg3 | |
| JP2012219031A (en) | LAMININ 5 PRODUCTION PROMOTER, INTEGRIN α6β4 PRODUCTION PROMOTER, SKIN BASEMENT MEMBRANE-NORMALIZING AGENT, SKIN DAMAGE-RESTORING PROMOTER, AND AQUAPORIN 3mRNA EXPRESSION PROMOTER | |
| KR102114682B1 (en) | Wrinkle improvement cosmetic containing ginsenoside Rg3, Rg5 and Rk1 | |
| KR20210131680A (en) | Composition for preventing hair loss or promoting hair growth comprising Pectin | |
| KR102543076B1 (en) | Composition comprising DNA components for suppressing specific gene expression, controlling epigenetic mutation, and improving skin condition | |
| EP3300738A1 (en) | Composition for wound treatment containing an extract of aerial parts of stellera chamaejasme | |
| JP6017259B2 (en) | Endothelin action inhibitor | |
| WO2017057929A1 (en) | Cosmetic composition for prevention of skin aging and amelioration of wrinkles containing a mixture extract of rosa multiflora thunberg hips and kochia scoparia schrader seeds | |
| KR101715590B1 (en) | 11- 1 Anti-aging cosmetic composition or skin external composition comprising compound of 11-hydroxysteroid dehydrogenase type 1 inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14886575 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 14886575 Country of ref document: EP Kind code of ref document: A1 |